This article was originally published by Cancer Network Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on...
News
Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple...
Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple...
Multiple myeloma triple therapy now on PBS
This article was originally published by Hostpital and Healthcare. Australians with newly diagnosed multiple myeloma (MM) can now access a treatment...
GNS Healthcare Launches In Silico Multiple Myeloma “Patient”
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have...
MRP a valuable risk assessment tool for newly diagnosed multiple myeloma
A clinical prediction model for myeloma has been shown to be “a robust and valuable tool” in a real-world population of Danish patients.
Dr. Hari on the Role of MRD in Multiple Myeloma
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin…
Study Identifies Independent Predictors of Smoldering Multiple Myeloma Progression
A series of molecular abnormalities in smoldering multiple myeloma that are independent predictors of progression to multiple myeloma were...
Article of the week: Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
Myeloma Australia's Medical and Scientific Advisory Group (MSAG) presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd)...
Australian clinicians report on real world use of bortezomib in elderly MM patients
Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who are older and more...
Article of the week: Once-versus twice-weekly car fi lzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Myeloma Australia's Medical and Scientific Advisory Group (MSAG) presents the article of the week. Multiple myeloma (MM) is the third most common...
Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or...